Hereditary Cardiovascular Testing

Starting on June 26, 2013, Ambry Genetics will no longer accept samples for some of its cardiovascular next generation sequencing (NGS) panels. Suspended panels include: Brugada syndrome, Long QT syndrome, Arrhythmia, DCM, HCM, Cardiomyopathy and Pan Cardio. We are offering TAADNext (NGS panel for Marfan syndrome, Aneurysms, and Related Disorders), and Familial Hypercholesterolemia testingIn the near future we plan to release updated, targeted cardiovascular NGS panels, with the addition of deletion/duplication analysis.


To better serve the growing needs of clinicians and patients, Ambry Genetics has expanded its cardiovascular genetics test offerings. We now offer multiple gene panels for hereditary cardiovascular diseases, including cardiomyopathies and arrhythmias.

Ambry’s new Pan Cardio Panel includes 79 genes that have been implicated in multiple cardiovascular diseases. Ambry also offers several smaller panels that include subsets of genes from the Pan Cardio Panel. These panels may be more specific to a particular person’s phenotype or clinical findings.